Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study.

Tobias MoserCiara O'SullivanFerdinand OttoWolfgang HitzlGeorg PilzKerstin SchwenkerCornelia MrazekElisabeth Haschke-BecherEugen TrinkaPeter WipflerAndrea Harrer

Published in: Therapeutic advances in neurological disorders (2022)

Anti-CD20-induced inhibition of humoral responses to COVID-19 vaccines is transient and antibody production was more pronounced >18 months after anti-CD20 treatment discontinuation. The immunological effect on B-cell counts appears to wane by the same time.

Keyphrases

coronavirus disease
multiple sclerosis
sars cov
immune response
nk cells
white matter
respiratory syndrome coronavirus
peripheral blood
cerebral ischemia
diabetic rats
brain injury
subarachnoid hemorrhage
combination therapy